The Telix Pharmaceuticals Ltd (ASX: TLX) share price rose more than 5% after announcing a Regeneron partnership.
Telix Pharmaceuticals is a global biopharmaceutical business that’s looking to develop and sell radiopharmaceuticals to address medical needs in oncology and rare diseases.
Regeneron is also a biotech company, which develops and sells life-transforming medicines for people with serious diseases.
Radiopharma partnership
The two businesses announced that they will co-develop and co-commercialise next-generation therapies in a 50/50 cost and profit-sharing model.
This collaboration will combine Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s leading antibody discovery and development platforms, as well as oncology experience.
The collaboration will include multiple solid tumor targets from Regeneron’s portfolio of antibodies, generated from VelocImmune mice.
Telix will receive US$40 million upfront for access to its radiopharmaceutical manufacturing platform four initial therapeutic programs, with optionality on a per-program basis to co-fund commercialisation and profit-sharing, or earn up to an aggregate of US$2.1 billion in development and commercial milestone payments plus low double-digit royalties.
Telix and Regeneron will share equally in the global commercialisation costs and potential profits, with Telix retaining the option to co-promote certain potential products.
If Telix opts out of the co-funding model for a particular program, it will be eligible to receive up to US$535 million in development and commercial milestones, plus low double-digit royalties on future net sales, for that program.
The ASX biotech share and Regeneron will also jointly develop diagnostic assets, with Telix leading commercialisation and Regeneron receiving a set of percentage profits.
Management comments
The Managing Director and CEO of Telix, Christian Behrenbruch, said:
The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics based radiopharmaceuticals can potentially do for patients.
We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers.
Final thoughts on the Telix Pharmaceutical share price
The business has suffered a decline of more than 40% in the past year, though it’s up 34% in 2026 to date. In other words, it has been very volatile!
I’m not an expert on biopharmaceuticals, so it’s hard to say if this is a good time to invest and how much of a difference this will make for Telix in the long-term.
For those reasons, it’s not one of the ASX growth shares I’m looking to invest in today because it’s hard to judge long-term earnings potential.
